Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023
22 mars 2023 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., March 22, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, CFO and co-CEO, will present a company overview at the Virtual Investor Summit...
Cocrystal Pharma Announces Participation in Virtual Investor Events
26 janv. 2023 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the participation of James Martin, co-CEO and CFO, in the following virtual investment community...
Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A
19 déc. 2022 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces highly favorable safety and tolerability results for its orally administered replication inhibitor...
Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022
01 déc. 2022 16h05 HE
|
Cocrystal Pharma, Inc.
Affirms plans to report topline Phase 1 results in 2022 and to initiate Phase 2a influenza human challenge trial in 2023 BOTHELL, Wash., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc....
Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A
17 nov. 2022 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) today announced that CC-42344 demonstrated a favorable safety profile in both the single-ascending dose and...
Cocrystal Pharma Reports Third Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
14 nov. 2022 08h00 HE
|
Cocrystal Pharma, Inc.
Completed enrollment in the Phase 1 study with novel, broad-spectrum antiviral PB2 candidate CC-42344 for the treatment of pandemic and seasonal influenza A; remains on track to report topline results...
Cocrystal Pharma to Participate in Two Investor Conferences in November
02 nov. 2022 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate in two upcoming investor conferences as follows: 2022 BioFlorida...
Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza
01 nov. 2022 16h05 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces it has been granted European patent EP3866778 titled "Combinations Of Inhibitors of Influenza Virus...
Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344
26 oct. 2022 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the completion of enrollment in a Phase 1 healthy volunteer study to assess the safety, tolerability...
Cocrystal Pharma to Present at the LD Micro Main Event XV
19 oct. 2022 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that President and co-interim CEO Sam Lee, PhD will present a company overview of their antiviral...